Under the terms of the agreement, ArunA has acquired an exclusive worldwide license to develop and commercialize human mesenchymal cells (hMSC) derived from human embryonic stem cells.
ArunA will offer the academic and industrial research communities access to a highly uniform population of human mesenchymal cells grown as adherent monolayer cultures in multiple turn-key kit formats.
The hMSC kits will provide a physiologically relevant and genetically stable source of research material for use in a broad range of life science research applications such as – developmental pathway studies, disease modeling, in vitro toxicology, compound screening and humanized animal models.
William Sharp, president and CEO of ArunA Biomedical, said: “ArunA’s proprietary adherent monolayer culture technology creates millions of highly uniform cells. These unique cells provide researchers with new enabling tools that can have a measurable impact on the advancement of drug discovery. We are targeting an early first quarter 2009 launch of ArunA’s first hMSC kit.”